Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis
Nature Medicine2000Vol. 6(9), pp. 1043–1047
Citations Over TimeTop 10% of 2000 papers
Related Papers
- → Plasma Concentrations of Isoniazid and Rifampin Are Decreased in Adult Pulmonary Tuberculosis Patients with Diabetes Mellitus(2013)74 cited
- → Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide(2012)40 cited
- → Quantification of pyrazinamide, isoniazid, acetyl‐isoniazid, and rifampicin by a high‐performance liquid chromatography method in human plasma from patients with tuberculosis(2020)19 cited
- → Comparative Efficacy of the Concurrent Use of Pyrazinamide and Isoniazid with That of Other Forms of Therapy in the Treatment of Pulmonary Tuberculosis(1957)4 cited
- → Effect of Pyrazinamide on Antimicrobially Active Serum Isoniazid(1960)